The purpose of this research was to develop the microemulsion based in situ gelling system containing moxifloxacin for prophylaxis and treatment of the posterior segment diseases like endophthalmitis. Moxifloxacin is well reported for the treatment of endophthalmitis, it has better penetration into ocular tissues and high potency compared to many of the same class drugs. Unlike halogenated fluoroquinolones it is safe to use in higher dose and is devoid of phototoxicity. So, moxifloxacin was used as a model drug. Formulation approach provides better absorption, penetration, retention and improves bioavailability of the drug. The average conc. reached into vitreous humor from topical microemulsion in situ gelling formulation was ~0.4 µg/ml, which is far more than concentration required for therapeutic effect (i.e. > 0.047 µg/ml or >>MIC90 for S. epidermidis, a pathogen commonly responsible to cause endophthalmitis). Thus, novel microemulsion based in-situ gelling formulation could be potential drug delivery system for treatment of posterior segment diseases like endophthalmitis.
Loading....